Oncolytic Transcriptionally Retargeted Adenovirus Expressing Nitroreductase in Combination with Antiangiogenic Drug RAD001

被引：0
|
作者：
Lukashev, Alexander N. [1 ]
Homicsko, Krizstian G. [1 ]
Fuerer, Cristophe [2 ]
Iggo, Richard [1 ]
机构：
[1] Univ St Andrews, Bute Med Sch, St Andrews, Fife, Scotland
[2] ISREC, Epalinges, Switzerland
来源：
MOLECULAR THERAPY | 2006年 / 13卷
关键词：
D O I：
10.1016/j.ymthe.2006.08.716
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
640
引用
收藏
页码：S246 / S246
页数：1
相关论文
共 50 条
  • [21] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1241 - 1246
  • [22] mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
    Lane, Heidi A.
    Wood, Jeanette M.
    McSheehy, Paul M. J.
    Allegrini, Peter R.
    Boulay, Anne
    Brueggen, Joseph
    Littlewood-Evans, Amanda
    Maira, Sauveur-Michel
    Martiny-Baron, Georg
    Schnell, Christian R.
    Sini, Patrizia
    O'Reilly, Terence
    CLINICAL CANCER RESEARCH, 2009, 15 (05) : 1612 - 1622
  • [23] Phase III Data in neuroendocrine Tumors show: RAD001 as Monotherapy and in Combination with Sandostatin© LAR© effectively
    Roth, Irene
    VISZERALMEDIZIN, 2010, 26 (04): : 290 - 290
  • [24] Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture
    Burckel, Helene
    Josset, Elodie
    Denis, Jean-Marc
    Gueulette, John
    Slabbert, Jakobus
    Noel, Georges
    Bischoff, Pierre
    ONCOLOGY REPORTS, 2015, 33 (01) : 471 - 477
  • [25] A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer
    Moulder, Stacy
    Gladish, Gregory
    Ensor, Joe
    Gonzalez-Angulo, Ana Maria
    Cristofanilli, Massimo
    Murray, James L.
    Booser, Daniel
    Giordano, Sharon H.
    Brewster, Abeena
    Moore, Julia
    Rivera, Edgardo
    Hortobagyi, Gabriel N.
    Tran, Hai T.
    CANCER, 2012, 118 (09) : 2378 - 2384
  • [26] Phase I Study of Sorafenib in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET)
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    PANCREAS, 2011, 40 (02) : 326 - 326
  • [27] Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple mycloma
    Mahindra, A. K.
    Richardson, P. G.
    Hari, P.
    Laubach, J.
    Ghobrial, I. M.
    Schlossman, R. L.
    Weller, E.
    Munshi, N. C.
    Anderson, K. C.
    Raje, N. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET)
    Chan, J. A.
    Mayer, R. J.
    Jackson, N.
    Malinowski, P.
    Regan, E.
    Kulke, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Improved Effect of Chemoradiotherapy in Combination with Oncolytic Adenovirus Expressing Interferon-α for Pancreatic Cancer
    Han, J.
    Armstrong, L.
    Brown, E.
    Aoki, K.
    Vickers, S.
    Yamamoto, M.
    Davydova, J.
    PANCREAS, 2011, 40 (08) : 1325 - 1325
  • [30] Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12
    Jiang, Haifei
    Nace, Rebecca
    Ferguson, Coryn
    Zhang, Lianwen
    Peng, Kah Whye
    Russell, Stephen J.
    CELL REPORTS MEDICINE, 2025, 6 (01)
12345